Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373265 · ClinicalTrials.gov registry record · Phase 1
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04373265 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04373265, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
Interventions
- DRUG Pembrolizumab
- DRUG Relacorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04373265
The ClinicalTrials.gov registry entry for NCT04373265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04373265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04373265 about?
NCT04373265 is a clinical study titled "Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)". This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
What is the current status of trial NCT04373265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-09-30. Estimated completion is 2024-01-12.
What interventions are being tested in trial NCT04373265?
The interventions under investigation include: Pembrolizumab (DRUG), Relacorilant (DRUG).
Who is sponsoring clinical trial NCT04373265?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.